RxDoctor Payments Data

Gregory Mullen, MD

Urology · Livingston, NJNPI 1689105504

Payments from drug & device makers

$3,088in general payments, 2019–2025

Across 39 payments — averaging $79.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Bayer$123
  • Novo Nordisk Health Care AG$114
  • Richard Wolf Medical Instruments Corp.$76
  • 180 Medical, Inc.$54
  • Novo Nordisk$46
  • plus $93 from 6 others

What the payments were for

  • Travel & lodging$1,01133%
  • Food & beverage$1,95363%
  • Education$1234%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific26$2,581
Bayer1$123
Novo Nordisk Health Care AG1$114
Richard Wolf Medical Instruments Corp.1$76
180 Medical, Inc.2$54
Novo Nordisk2$46
Sumitomo Pharma America, Inc.1$18
Coloplast1$18
C. R. Bard, Inc. & Subsidiaries1$16
Blue Earth Diagnostics1$14
Hollister Incorporated1$14
ABC Home Medical Supply, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,088 in reported general payments places this provider in the 55th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$260,245
Medicare patients
610
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron31$22,405
GemtesaVibegron19$14,852
Tamsulosin Hcl173$2,974
Potassium Citrate ErPotassium Citrate30$2,821
Estradiol31$1,975
Methenamine Hippurate26$1,849
Silodosin12$939
Solifenacin Succinate24$705
Finasteride37$520
Ciprofloxacin Hcl47$230
Cephalexin49$214
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$18$14,85219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 401 urology providers in New Jersey.

Other urology in Livingston

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →